NEWS
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.
An oral presentation by Dr. Christine Chung will discuss a phase 1 study of CUE-101 as monotherapy and in combination with pembrolizumab for HPV16+ head and neck squamous cell cancer. A poster presentation by Dr. Dae Won Kim will cover a phase 1 trial of CUE-102 for WT1-positive recurrent/metastatic cancers in HLA-A*0201 positive patients.
The oral presentation is scheduled for November 8, 2024, and the poster will be displayed on November 9, 2024. Both presentations will be available as virtual e-posters from November 7, 2024, to January 7, 2025, and on the company's website from November 8, 2024.
An oral presentation by Dr. Christine Chung will discuss a phase 1 study of CUE-101 as monotherapy and in combination with pembrolizumab for HPV16+ head and neck squamous cell cancer. A poster presentation by Dr. Dae Won Kim will cover a phase 1 trial of CUE-102 for WT1-positive recurrent/metastatic cancers in HLA-A*0201 positive patients.
The oral presentation is scheduled for November 8, 2024, and the poster will be displayed on November 9, 2024. Both presentations will be available as virtual e-posters from November 7, 2024, to January 7, 2025, and on the company's website from November 8, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1686Followers
93Following
13KVisitors
Follow